Document:

EX-4.5

 Exhibit 4.5 
 NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THIS WARRANT MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF THIS WARRANT. 
 WARRANT AGREEMENT 
 To Purchase Shares of Preferred Stock of 

BIND THERAPEUTICS, INC. 
 Dated as of June 12, 2013 (the “Effective Date”) 
 WHEREAS,
BIND THERAPEUTICS, INC., a Delaware corporation (the “Company”), has entered into an Amended and Restated Loan and Security Agreement of even date herewith (the “Loan Agreement”) with Hercules Technology III, L.P.,
a Delaware limited partnership (the “Warrantholder”); 
 WHEREAS, the Company desires to grant to
Warrantholder, in consideration for, among other things, the financial accommodations provided for in the Loan Agreement, the right to purchase shares of Preferred Stock (as defined below) pursuant to this Warrant Agreement (the
“Agreement”); 
 NOW, THEREFORE, in consideration of the Warrantholder executing and delivering the Loan
Agreement and providing the financial accommodations contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: 

SECTION 1. GRANT OF THE RIGHT TO PURCHASE PREFERRED STOCK. 

For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the
conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to the aggregate number of shares of fully paid and non-assessable shares of the Preferred Stock (as defined below) as is equal to the quotient derived by dividing
(a) $369,628 by (b) the Exercise Price (as defined below), at a purchase price per share equal to the Exercise Price. The aggregate number of shares of Preferred Stock that the Warrantholder may initially subscribe for and purchase under
this Agreement shall equal the quotient derived by dividing (a) $221,777 by (b) the Exercise Price. If the Company obtains the Second Advance (as defined in and pursuant to the Loan Agreement), then the aggregate number of shares of
Preferred Stock that the Warantholder may subscribe for and purchase under this Agreement shall be increased by an amount equal to the quotient derived by dividing (a) $147,851 by (b) the Exercise Price. The number of shares and Exercise
Price are subject to adjustment as provided in Section 8. As used herein, the following terms shall have the following meanings: 

 “Act” means the Securities Act of 1933, as amended. 

“Charter” means the Company’s Certificate of Incorporation or other constitutional document, as may be amended
and/or restated from time to time. 
 “Common Stock” means the Company’s common stock, $0.0001 par value
per share. 
 “Equity Financing” means the first private institutional equity financing of the Company
generating cash proceeds of at least $5,000,000 that is consummated after the date hereof and prior to the effective date of the registration statement for the Initial Public Offering, including any stock of the Company actually issued upon
conversion of convertible debt of the Company. 
 “Exercise Price” means a price equal to the lower of
(a) $6.00 per share if this Agreement is exercised for Series D Preferred Stock (as defined below) or (b) the effective price per share paid in the Equity Financing if this Agreement is exercised for securities sold in the Equity
Financing, in each case, subject to adjustment from time to time as provided in this Agreement. 
 “Initial Public
Offering” means the initial underwritten public offering of Common Stock pursuant to a registration statement under the Act, which registration statement for the public offering has been declared effective by the Securities and Exchange
Commission (“SEC”). 
 “Merger Event” means a merger or consolidation involving the Company in
which the Company is not the surviving entity or in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of capital stock of another entity. 

“Preferred Stock” means the Series D Convertible Preferred Stock, $0.0001 par value per share, of the Company (the
“Series D Preferred Stock”) and any other stock into or for which the Series D Preferred Stock may be converted or exchanged; provided, that if Warrantholder exercises its right under Section 8(g) of this Agreement to have the
class and series of equity securities issued in the Equity Financing issuable upon exercise of this Warrant, then the Preferred Stock shall be of the class and type sold in such financing and any other stock into or for which such Preferred Stock
may be converted or exchanged. Upon and after the occurrence of an event which results in the automatic or voluntary conversion, redemption or retirement of all (but not less than all) of the outstanding shares of such Preferred Stock, including,
without limitation, the consummation of an Initial Public Offering of the Common Stock in which such a conversion occurs, then from and after the date upon which such outstanding shares are so converted, redeemed or retired, (i) this Warrant
shall be exercisable for such number of shares of Common Stock as is equal to the number of shares of Common Stock that each share of Preferred Stock was converted into, multiplied by the number of shares of Preferred Stock subject to this Warrant
immediately prior to such conversion, (ii) the Purchase Price shall be the Purchase Price in effect immediately prior to such conversion divided by the number of shares of Common Stock into which each share of Preferred Stock was converted, and
(iii) all references to this Warrant to “Preferred Stock” shall thereafter be deemed to refer to “Common Stock.” Notwithstanding the foregoing, in no event shall “Preferred Stock” include any debt security or other
evidences of indebtedness of the Company. 

  
 2 

 “Purchase Price” means, with respect to any exercise of this Agreement, an
amount equal to the Exercise Price as of the relevant time multiplied by the number of shares of Preferred Stock requested to be exercised under this Agreement pursuant to such exercise. 

“Rights Agreement” means that certain Fourth Amended and Restated Investors’ Rights Agreement, between the Company
and certain of its stockholders, dated November 7, 2011, as may be amended and/or restated from time to time (including, without limitation, that certain Amendment No. 1 to Fourth Amended and Restated Investors’ Rights Agreement,
dated January 23, 2013). 
 “Series C-1 Warrant” means that certain Warrant Agreement, between the Company
and the Warrantholder, dated January 10, 2011, as may be amended and/or restated from time to time. 
 SECTION 2.
TERM OF THE AGREEMENT. 
 Except as otherwise provided for herein, the term of this Agreement and the right to purchase
Preferred Stock as granted herein (the “Warrant”) shall commence on the Effective Date and shall be exercisable for a period ending upon the later to occur of (i) ten (10) years from the Effective Date; and (ii) five
(5) years following the effective date of the registration statement for the Initial Public Offering, if any, that occurs before the tenth anniversary of the Effective Date (the later of (i) and (ii), the “Expiration
Date”). 
 SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any
time, or from time to time, prior to the Expiration Date, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”), duly completed and
executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than five (5) business days thereafter, the Company shall issue to the
Warrantholder a certificate for the number of shares of Preferred Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the
number of shares which remain subject to future exercises, if any. 
 The Purchase Price may be paid at the Warrantholder’s
election either (i) by cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Preferred Stock to be exercised under this Agreement and, if applicable, an amended Agreement representing the remaining number of
shares purchasable hereunder, as determined below (“Net Issuance”). If the Warrantholder elects the Net Issuance method of exercise, the Company will issue Preferred Stock in accordance with the following formula: 

 

			
	X =	 	Y(A-B)
	 	    A

  

	Where:	  X = the number of shares of Preferred Stock to be issued to the Warrantholder. 

Y = the number of shares of Preferred Stock requested to be exercised under this Agreement. 

A = the fair market value of one (1) share of Preferred Stock at the time of issuance of such shares of Preferred
Stock. 
 B = the Exercise Price. 

  
 3 

 For purposes of the above calculation, current fair market value of Preferred Stock shall
mean with respect to each share of Preferred Stock: 
 (i) if the exercise is in connection with an Initial
Public Offering, and if the Company’s Registration Statement relating to such Initial Public Offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to
Public” of the Common Stock specified in the final prospectus with respect to the offering and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 

(ii) if the exercise is after, and not in connection with, an Initial Public Offering, then: 

(A) if the Common Stock is traded on a securities exchange, then the fair market value shall be deemed to be the product
of (x) the average of the closing prices over a five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which
each share of Preferred Stock is convertible at the time of such exercise; or 
 (B) if the Common Stock is
traded over-the-counter, then the fair market value shall be deemed to be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day period ending three
(3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 

(iii) if at any time the Common Stock is not listed on any securities exchange or quoted in the NASDAQ National Market or
the over-the-counter market, the current fair market value of Preferred Stock shall be the product of (x) the fair market value of Common Stock as determined in good faith by its Board of Directors and (y) the number of shares of Common
Stock into which each share of Preferred Stock is convertible at the time of such exercise, provided that in the event that the exercise is in connection with a Merger Event, the fair market value of Preferred Stock shall be deemed to be the per
share value received by the holders of the Preferred Stock on an as-converted-to common stock basis pursuant to such Merger Event. 
 Upon partial exercise by either cash or Net Issuance, the Company shall promptly issue an amended Agreement representing the remaining number of shares of Preferred Stock purchasable hereunder. All other
terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective Date hereof. 
 (b) Exercise Prior to Expiration. To the extent this Agreement is not previously exercised as to all Preferred Stock subject hereto, and if the fair market value of one share of the Preferred Stock
is greater than the Exercise Price then in effect, this Agreement shall be deemed automatically exercised pursuant to Section 3(a) (even if not surrendered) immediately prior to the Expiration Date. For purposes of such automatic exercise, the
fair market value of one share of the Preferred Stock upon such Expiration Date shall be determined pursuant to Section 3(a). To the extent this Agreement or any portion thereof is deemed automatically exercised pursuant to this
Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Preferred Stock, if any, the Warrantholder is to receive by reason of such automatic exercise. 

  
 4 

 SECTION 4. RESERVATION OF SHARES. 

During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Series
D Preferred Stock to provide for the exercise of the rights to purchase Series D Preferred Stock as provided for herein, and shall have authorized and reserved a sufficient number of shares of Common Stock to provide for the conversion of the Series
D Preferred Stock available hereunder. 
 SECTION 5. NO FRACTIONAL SHARES OR SCRIP. 

No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such
fractional shares, the Company shall make a cash payment therefor in an amount equal to the product of (i) the Exercise Price then in effect multiplied by (ii) the fraction of a share. 

SECTION 6. REGISTRATION RIGHTS; NO OTHER RIGHTS AS STOCKHOLDER. 

The Rights Agreement provides that the Common Stock into which the Preferred Stock is convertible shall be “Registrable
Securities”, and Warrantholder shall have the rights of, and be subject to the obligations of, a “Holder” under the Section 3 of the Rights Agreement. This Agreement does not entitle the Warrantholder to any voting rights or
other rights as a stockholder of the Company prior to the exercise of this Agreement. 
 SECTION 7. WARRANTHOLDER
REGISTRY. 
 The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. The
Warrantholder’s initial address, for purposes of such registry, is set forth in Section 12(e) of this Agreement. The Warrantholder may change such address by giving written notice of such changed address to the Company. 

SECTION 8. ADJUSTMENT RIGHTS. 
 The Exercise Price and the number of shares of Preferred Stock purchasable hereunder are subject to adjustment, as follows: 
 (a) Merger Event. If at any time there shall be Merger Event, then, as a part of such Merger Event, lawful provision shall be made so that the Warrantholder shall thereafter be entitled to receive,
upon exercise of this Agreement, the number of shares of capital stock or other securities or cash or other property resulting from such Merger Event that would have been issuable if Warrantholder had exercised this Agreement immediately prior to
the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions of this Agreement with respect to the rights and interests of the
Warrantholder after the Merger Event to the end that the provisions of this Agreement (including adjustments of the Exercise Price and number of shares of Preferred Stock purchasable) shall be applicable in their entirety and to the greatest extent
possible. Without limiting the foregoing, in connection with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the obligations of this Agreement. In connection with a Merger Event and upon
Warrantholder’s written election to the Company at least ten (10) days prior to the effectiveness of such Merger Event, the Company shall cause this Warrant Agreement to be exchanged for the consideration that Warrantholder would have
received if Warrantholder chose to exercise its right to have shares issued pursuant to the Net Issuance provisions of this Warrant Agreement, without actually exercising such right, acquiring such shares, and exchanging such shares for such
consideration. 

  
 5 

 (b) Reclassification of Shares. Except as set forth in Section 8(a), if the
Company at any time shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of
the same class or any other class or classes, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were
subject to the purchase rights under this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. 
 (c) Subdivision or Combination of Shares. If the Company at any time shall subdivide or combine its Preferred Stock, (i) in the case of a subdivision, the Exercise Price shall be
proportionately decreased, and the number of shares of Preferred Stock issuable upon exercise of this Agreement shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be proportionately increased, and
the number of shares of Preferred Stock issuable upon the exercise of this Agreement shall be proportionately decreased. 
 (d)
Stock Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall: 

(i) pay a dividend with respect to the Preferred Stock payable in Preferred Stock, then the Exercise Price shall be
adjusted, from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction
(A) the numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Preferred Stock
outstanding immediately after such dividend or distribution; or 
 (ii) make any other distribution with respect
to Preferred Stock (or stock into which the Preferred Stock is convertible), except any distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the
Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of any such distribution as though it were the holder of the Preferred Stock (or other stock for which the Preferred Stock is convertible) as of the record
date fixed for the determination of the stockholders of the Company entitled to receive such distribution. 
 (e) Antidilution
Rights. Additional antidilution rights applicable to the Preferred Stock purchasable hereunder are as set forth in the Charter and shall be applicable with respect to the Preferred Stock issuable hereunder. The Company shall promptly provide the
Warrantholder with any restatement, amendment, modification or waiver of the Charter; provided, that no such amendment, modification or waiver shall impair or reduce the antidilution rights applicable to the Preferred Stock as of the date
hereof unless such amendment, modification or waiver applies to all then outstanding shares of Preferred Stock. For the avoidance of doubt, there shall be no duplicate anti-dilution adjustment pursuant to this subsection (e), the forgoing subsection
(d) and the Charter. 
 (f) Notice of Adjustments. If: (i) the Company shall declare any dividend or
distribution upon its stock, whether in stock, cash, property or other securities; (ii) the Company shall offer for subscription pro rata to the holders of any class of its Preferred Stock or other convertible stock any additional shares of
stock of any class or other rights; (iii) there shall be any Merger Event; (iv) there shall be an Initial Public Offering; (v) the Company shall sell, lease, exclusive license or otherwise transfer all or substantially all of its
assets; or (vi) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall send to the Warrantholder: (A) at least ten (10) days’ prior written
notice of the date on which the books of the Company shall close or a record shall be taken for 

  
 6 

 
such dividend, distribution, subscription rights (specifying the date on which the holders of Preferred Stock shall be entitled thereto) or for determining rights to vote in respect of such
Merger Event, dissolution, liquidation or winding up; (B) in the case of any such Merger Event, sale, lease, exclusive license or other transfer of all or substantially all assets, dissolution, liquidation or winding up, at least ten
(10) days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders of Preferred Stock shall be entitled to exchange their Preferred Stock for securities or other property deliverable
upon such Merger Event, dissolution, liquidation or winding up); and (C) in the case of an Initial Public Offering, the Company shall give the Warrantholder at least five (5) days’ written notice prior to the effective date of the
registration statement therefor. 
 Each such written notice shall set forth, in reasonable detail, (i) the event requiring
the notice, and (ii) if any adjustment is required to be made, (A) the amount of such adjustment, (B) the method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted),
and (D) the number of shares subject to purchase hereunder after giving effect to such adjustment. Such written notice shall be given by first class mail, postage prepaid, by reputable overnight courier with all charges prepaid or via
electronic transmission, addressed to the Warrantholder at the address for Warrantholder set forth in Section 12(g). 
 (g)
Election. If (i) none of the purchase rights set forth in this Agreement have been previously exercised and (ii) the Initial Public Offering has not been consummated, then at least ten (10) days prior to the consummation of the
Equity Financing, the Company shall give written notice to the Warrantholder of such Equity Financing (the “Financing Notice”) setting forth a summary of the material terms of such Equity Financing. For the avoidance of doubt, the
issuance of securities in connection with a research, collaboration, technology license, development, marketing or other similar agreement or strategic partnership shall not be an Equity Financing. Within three (3) business days following the
date of such Financing Notice, the Warrantholder shall deliver written notice to the Company electing to have the class and series of equity securities issued in such Equity Financing (instead of Series D Preferred Stock) be the securities issuable
upon exercise of this Warrant. If Warrantholder fails to exercise such right in a timely manner, the rights of Warrantholder under this Section 8(g) shall terminate immediately and the Company shall have no further obligation under this
Section 8(g). 
 SECTION 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

The Company makes the following representations and warranties to Warrantholder as of the Effective Date. 

(a) Reservation of Preferred Stock. The Series D Preferred Stock issuable upon exercise of the Warrantholder’s rights under
this Agreement has been duly and validly reserved and, when the Preferred Stock is issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or
encumbrances of any nature whatsoever; provided, that the Preferred Stock issuable pursuant to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws. The Company has made available to the
Warrantholder true, correct and complete copies of its Charter and bylaws currently in effect. The issuance of certificates for shares of Preferred Stock upon exercise of this Agreement shall be made without charge to the Warrantholder for any
issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of Preferred Stock; provided, that the Company shall not be required to pay any tax which may be
payable in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder. 

  
 7 

 (b) Due Authority. The execution and delivery by the Company of this Agreement and
the performance of all obligations of the Company hereunder, including the issuance to Warrantholder of the right to acquire the shares of Preferred Stock and the Common Stock into which it may be converted, have been duly authorized by all
necessary corporate action on the part of the Company. This Agreement: (1) does not violate the Charter or current bylaws; (2) does not contravene any law or governmental rule, regulation or order applicable to it; and (3) does not
and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes a legal, valid and binding agreement of the
Company, enforceable in accordance with its terms except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights generally, and
(b) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. 
 (c) Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, federal or other governmental authority or
agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state
securities law, which filings will be effective by the time required thereby. 
 (d) Issued Securities. All issued and
outstanding shares of Common Stock, Series D Preferred Stock or any other securities of the Company have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of securities were issued in full
compliance with all federal and state securities laws. In addition, as of the Effective Date: 
 (i) The
authorized capital of the Company consists of (A) 43,500,000 shares of Common Stock, of which 6,128,855 shares are issued and outstanding, (B) 2,461,600 shares of Series A Convertible Preferred Stock, of which 2,461,600 shares are issued
and outstanding and are convertible into 2,461,600 shares of Common Stock, (C) 6,458,000 shares of Series B Convertible Preferred Stock, of which 6,450,000 shares are issued and outstanding and are convertible into 6,450,000 shares of Common
Stock, (D) 3,520,000 shares of Series C Convertible Preferred Stock, of which 3,520,000 shares are issued and outstanding and are convertible into 3,520,000 shares of Common Stock, (E) 5,255,238 shares of Series C-1 Convertible Preferred
Stock, of which 3,105,238 shares are issued and outstanding and are convertible into 3,105,238 shares of Common Stock, (F) 7,249,412 shares of Series D Convertible Preferred Stock, of which 6,773,640 shares are issued and outstanding and are
convertible into 6,773,640 shares of Common Stock and (G) 3,291,667 shares of Series BRN Convertible Preferred Stock, of which 583,333 shares are issued and outstanding and are convertible into 729,167 shares of Common Stock. 

(ii) The Company has reserved 8,000,000 shares of Common Stock for issuance under its 2006 Stock Incentive Plan, under
which options to purchase an aggregate of 5,785,369 shares of Common Stock are outstanding. Other than under the 2006 Stock Incentive Plan, a warrant to purchase an aggregate of 8,000 shares of Series B Convertible Preferred Stock, the Series C-1
Warrant and the preferred stock described in clause (i) above, there are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the
Company’s capital stock or other securities of the Company. 

  
 8 

 (iii) Except as set forth in the Rights Agreement, no stockholder of the
Company has preemptive rights to purchase new issuances of the Company’s capital stock. 
 (e) Other Commitments to
Register Securities. Except as set forth in this Agreement, the Series C-1 Warrant and the Rights Agreement, the Company is not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the Act
any of its presently outstanding securities or any of its securities which may hereafter be issued. 
 (f) Exempt
Transaction. Subject to the accuracy of the Warrantholder’s representations set forth in Section 10, the issuance of the Preferred Stock upon exercise of this Agreement, and the issuance of the Common Stock upon conversion of the
Preferred Stock, will each constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act and (ii) the qualification requirements of the applicable state securities laws. 

(g) Compliance with Rule 144. If the Warrantholder proposes to sell Preferred Stock issuable upon the exercise of this Agreement,
or the Common Stock into which it is convertible, in compliance with Rule 144 promulgated by the SEC, then, upon the Warrantholder’s written request to the Company, the Company shall furnish to the Warrantholder, within ten (10) days after
receipt of such request, a written statement indicating whether the Company is in compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time. 

(h) Information Rights. During the term of this Warrant, the Company shall furnish to the Warrantholder the reports that it
furnishes to the Major Stockholders (as defined in the Rights Agreement) pursuant to Section 1.1 of the Rights Agreement. 

SECTION 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder:

 (a) Investment Purpose. This Agreement and the Preferred Stock issuable upon exercise of the Warrantholder’s
rights contained herein are and will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution of the same except
pursuant to a registration or exemption. 
 (b) Private Issue. The Warrantholder understands (i) that the Preferred
Stock issuable upon exercise of this Agreement is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement will be exempt from the registration and qualifications
requirements thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 
 (c) Financial Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability
to bear the economic risks of its investment. 
 (d) Risk of No Registration. The Warrantholder understands that if the
Company does not register with the SEC pursuant to Section 12 of the Securities Exchange Act of 1934 (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering the
securities under the Act is not in effect when it desires to sell (i) the rights to purchase Preferred Stock pursuant to this Agreement or (ii) the Preferred Stock issuable upon exercise of the right to purchase, it may be required to hold
such securities for an indefinite period. The Warrantholder also understands that any sale of (A) its rights hereunder to purchase Preferred Stock or (B) Preferred Stock issued or issuable hereunder which might be made by it in reliance
upon Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule. 

  
 9 

 (e) Accredited Investor. Warrantholder is an “accredited investor” within
the meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 
 (f) Market
“Stand-off” Agreement. Warrantholder agrees, if requested by the Company, (a) not to (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, this Warrant, the Preferred Stock or other shares of capital stock issuable upon exercise of this Warrant (or the
conversion of any such shares), or any other securities of the Company or (ii) enter into any swap or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of this Warrant, the Preferred Stock or
other shares of capital stock issuable upon exercise of this Warrant (or the conversion of any such shares), or any other securities of the Company (excluding securities acquired in the Initial Public Offering or in the public market after the
Initial Public Offering), whether any transaction described in clause (i) or (ii) is to be settled by delivery of securities, in cash or otherwise, during the period beginning on the date of the filing of the registration statement
relating to the Initial Public Offering with the SEC and ending 180 days after the date of the final prospectus relating to the Initial Public Offering (plus up to an additional 34 days to the extent requested by the managing underwriters for such
offering in order to address Rule 2711(f) of the National Association of Securities Dealers, Inc. or any similar successor provision) and (b) to execute any agreement reflecting clause (a) above as may be requested by the Company or the
managing underwriters of the Initial Public Offering. In order to enforce the foregoing, the Company may impose stop-transfer instructions with respect to such securities until the end of such lock-up period and may cause such securities to bear a
legend setting forth such restriction until the end of such lock-up period. The underwriters for the Initial Public Offering are intended third party beneficiaries of this Section 10(f) and shall have the right, power and authority to enforce
the provisions hereof as though they were parties hereto. This Section 10(f) shall be effective only if all of the officers, directors, and holders of more than 5% of the Company’s Preferred Stock are bound by the same provisions.

 SECTION 11. TRANSFERS. 
 Subject to compliance with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in whole and not in part, without charge to the holder hereof (except for
transfer taxes) upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when endorsed in blank, shall be deemed negotiable, and that the
holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other persons dealing with this Agreement as the absolute owner hereof for any purpose and
as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit
III (the “Transfer Notice”) at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the Company receives such Transfer Notice, the Company may
treat the registered owner hereof as the owner for all purposes. Notwithstanding the foregoing, this Agreement shall not be transferable to any competitor of the Company prior to the Initial Public Offering (as determined in good faith by the Board
of Directors of the Company). 

  
 10 

 SECTION 12. MISCELLANEOUS. 

(a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had
been executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company and the Warrantholder. 
 (b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not
limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where the non-defaulting party will not have an adequate remedy at law and where damages will not be readily ascertainable.
Each party expressly agrees that it shall not oppose an application by the other party or any other person entitled to the benefit of this Agreement requiring specific performance of any or all provisions hereof or enjoining a party from continuing
to commit any such breach of this Agreement. 
 (c) Additional Documents. The Company, upon execution of this Agreement,
shall provide the Warrantholder with certified resolutions with respect to the representations, warranties and covenants set forth in Sections 9(a) through 9(d) and 9(f). 
 (d) Attorney’s Fees. In any litigation, arbitration or court proceeding between the Company and the Warrantholder relating hereto, the prevailing party shall be entitled to attorneys’
fees and expenses and all costs of proceedings incurred in enforcing this Agreement. For the purposes of this Section 12(d), attorneys’ fees shall include without limitation fees incurred in connection with the following: (i) contempt
proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions
and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment. 
 (e)
Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or
unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. 

(f) Notices. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process
or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the
earlier of: (i) the day of transmission by facsimile, electronic transmission or hand delivery if such transmission or delivery occurs on a business day at or before 5:00 pm in the time zone of the recipient, or, if transmission or delivery
occurs on a non-business day or after such time, the first business day thereafter, or the first business day after deposit with an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in
the United States mails, with proper first class postage prepaid, and shall be addressed to the party to be notified as follows: 
 If to Warrantholder: 
 Hercules Technology III, L.P. 

Legal Department 
 Attention: Chief Legal Officer and Manuel Henriquez 
 400 Hamilton Avenue, Suite
310 
 Palo Alto, CA 94301 
 Facsimile: 650-473-9194 
 Telephone: 650-289-3060 

Email: pshah@herculestech.com 

  
 11 

 If to the Company: 
 BIND THERAPEUTICS, INC. 
 325 Vassar Street 

Cambridge, MA 02139 
 Attention: Chief Financial Officer 
 Facsimile: 617-491-0351 

Telephone: 617-491-3400 x250 
 Email: ahirsch@bindtherapeutics.com 
 With a copy to: 

Latham & Watkins LLP 
 John Hancock Tower, 20th Floor 
 200 Clarendon Street 

Boston, MA 02116 
 Attention: Peter Handrinos 
 Facsimile: 617-948-6001 

Telephone: 617-948-6060 
 Email: peter.handrinos@lw.com 
 or to such other address as each party may designate for itself by
like notice, provided that any notice delivered to Warrantholder or Company shall be valid notwithstanding the failure to deliver a copy of such notice to any other person or entity. 

(g) Entire Agreement; Amendments. This Agreement constitute the entire agreement and understanding of the parties hereto in respect
of the subject matter hereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof. None of the terms
of this Agreement may be amended except by a written instrument executed by each of the parties hereto. 
 (h) Headings.
The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement or any provisions hereof. 
 (i) No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises,
this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 

(j) No Waiver. No omission or delay by Warrantholder at any time to enforce any right or remedy reserved to it, or to require
performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or remedy to which Warrantholder is entitled, nor shall it in any way affect the right of Warrantholder to
enforce such provisions thereafter. 
 (k) Survival. All agreements, representations and warranties contained in this
Agreement or in any document delivered pursuant hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement. 

  
 12 

 (l) Governing Law. This Agreement shall be governed by, and construed and enforced in
accordance with, the laws of the State of Delaware, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 
 (m) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any state or federal court of competent jurisdiction located in
Santa Clara County, State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County, California; (b) waives any objection as to
jurisdiction or venue in Santa Clara County, California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in
connection with this Agreement. 
 (n) Mutual Waiver of Jury Trial. Because disputes arising in connection with complex
financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved
by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY,
“CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY THE WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons other than the Company and
Warrantholder; Claims that arise out of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind,
arising out of this Agreement. 
 (o) Counterparts. This Agreement and any amendments, waivers, consents or supplements
hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same
instrument. 
 (p) Specific Performance. The parties hereto hereby declare that it is impossible to measure in money the
damages which will accrue to Warrantholder or Company by reason of the other’s failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be specifically enforceable by Warrantholder and
Company, as applicable. If Warrantholder or Company institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that the
instituting entity has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 

  
 13 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its officers thereunto
duly authorized as of the Effective Date. 
  

					
	 COMPANY:
	 	BIND THERAPEUTICS, INC.
			
		 	By:	 	/s/ Andrew Hirsch
		 	Title:	 	Chief Financial Officer
		
	 WARRANTHOLDER:
	 	HERCULES TECHNOLOGY III, L.P.,
		 	a Delaware limited partnership
		 	By:	 	Hercules Technology SBIC Management, LLC,
		 	its General Partner
		 	By:	 	Hercules Technology Growth Capital, Inc.,
		 	its Manager
			
		 	By:	 	/s/ Ben Bang
		 	Title:	 	Senior Counsel

 EXHIBIT I 
 NOTICE OF EXERCISE 
  

	To:	BIND THERAPEUTICS, INC. 

  

	(1)	The undersigned Warrantholder hereby elects to purchase [            ] shares of the Series
[    ] Preferred Stock of [                    ], pursuant to the terms of the Agreement dated the [    ] day
of [            ,         ] (the “Agreement”) between
[                    ] and the Warrantholder, and [CASH PAYMENT: tenders herewith payment of the Purchase Price in full, together with all applicable
transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.] 

  

	(2)	Please issue a certificate or certificates representing said shares of Series [    ] Preferred Stock in the name of the undersigned or in such other
name as is specified below. 

  

							
		 		 	  

		 		 	(Name)
			
		 		 	  

		 		 	(Address)
		
	WARRANTHOLDER:	 	HERCULES TECHNOLOGY III, L.P.,
		 	a Delaware limited partnership
		 	By:	 	Hercules Technology SBIC Management, LLC,
		 	its General Partner
		 	By:	 	Hercules Technology Growth Capital, Inc.,
		 	its Manager
				
		 		 	By:	 	  

		 		 	Title:	 	  

		 		 	Date:	 	  

 EXHIBIT II 
 ACKNOWLEDGMENT OF EXERCISE 
 The undersigned
[                                        ],
hereby acknowledge receipt of the “Notice of Exercise” from Hercules Technology III, L.P. to purchase [            ] shares of the Series [    ] Preferred
Stock of [                    ], pursuant to the terms of the Agreement, and further acknowledges that
[            ] shares remain subject to purchase under the terms of the Agreement. 
  

					
	 COMPANY:
	 	BIND THERAPEUTICS, INC.
			
		 	By:	 	 
		 	Title:	 	 
		 	Date:	 	 

  
 16 

 EXHIBIT III 
 TRANSFER NOTICE 
 (To transfer or assign the foregoing Agreement execute this form and supply
required information. Do not use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced thereby
are hereby transferred and assigned to 
  
  

(Please Print) 
 whose address
is                                        
                                         
    
  
  

 

			
	
Dated:                       
                                         
                         

		
	 Warrantholder’s Signature:
	 	 
		 	
	 Warrantholder’s Address:
	 	 
		
		 	 

  
 17EX-10.1

 Exhibit 10.1 
 BIND BIOSCIENCES, INC. 
 2006 Stock Incentive Plan 

 

	1.	Purpose. 

 The purpose of
this plan (the “Plan”) is to secure for BIND Biosciences, Inc., a Delaware corporation (the “Company”) and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and
consultants or advisors to, the Company and its parent and subsidiary corporations who are expected to contribute to the Company’s future growth and success. Under the Plan recipients may be awarded both (i) Options (as defined in
Section 2.1) to purchase the Company’s common stock, par value $0.0001 (“Common Stock”) and (ii) shares of the Company’s Common Stock (“Restricted Stock Awards”). Except where the context otherwise requires,
the term “Company” shall include any parent and all present and future subsidiaries of the Company as defined in Sections 424(e) and 424(f) of the Internal Revenue Code of 1986, as amended or replaced from time to time (the
“Code”). Those provisions of the Plan which make express reference to Section 422 of the Code shall apply only to Incentive Stock Options (as that term is defined below). 

 

	2.	Types of Awards and Administration. 

  

	 	2.1	Options. Options granted pursuant to the Plan (“Options”) shall be authorized by action of the Board of Directors of BIND Biosciences, Inc. (the
“Board” or “Board of Directors”) and may be either incentive stock options (“Incentive Stock Options”) meeting the requirements of Section 422 of the Code or non-statutory Options which are not intended to meet the
requirements of Section 422. The vesting of Options may be conditioned upon the completion of a specified period of employment with the Company and/or such other conditions or events as the Board may determine. The Board may also provide that
Options are immediately exercisable subject to certain repurchase rights in the Company dependent upon the continued employment of the optionee and/or such other conditions or events as the Board may determine. 

 

	 	2.1.1	 Incentive Stock Options. All Options when granted are intended to be non-statutory Options, unless the applicable Option Agreement (as defined
in Section 5.1) explicitly states that the Option is intended to be an Incentive Stock Option. Incentive Stock Options may only be granted to employees of the Company. For so long as the Code shall so provide, Options granted to any employee
under the Plan (and any other incentive stock option plans of the Company) which are intended to constitute Incentive Stock Options shall not constitute Incentive Stock Options to the extent that such Options, in the aggregate, become exercisable
for the first time in any one calendar year for shares of Common Stock with an aggregate fair market value (determined as of the 

  
 A-1

	 	
respective date or dates of grant) of more than $100,000. If an Option is intended to be an Incentive Stock Option, and if for any reason such Option (or any portion thereof) shall not qualify as
an Incentive Stock Option, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as a non-statutory Option appropriately granted under the Plan provided that such Option (or portion thereof) otherwise meets
the Plan’s requirements relating to non-statutory Options. 

  

	 	2.2	Restricted Stock Awards. The Board in its discretion may grant Restricted Stock Awards, entitling the recipient to acquire, for a purchase price determined by
the Board, shares of Common Stock subject to such restrictions and conditions as the Board may determine at the time of grant (“Restricted Stock”), including continued employment and/or achievement of pre-established performance goals and
objectives. 

  

	 	2.3	Administration. The Plan shall be administered by the Board, whose construction and interpretation of the terms and provisions of the Plan shall be final and
conclusive. The Board may in its sole discretion issue Restricted Stock and grant Options and issue shares upon exercise of such Options as provided in the Plan. The Board shall have authority, subject to the express provisions of the Plan, to
construe Restricted Stock Agreements, Option Agreements and the Plan, to prescribe, amend and rescind rules and regulations relating to the Plan, to determine the terms and provisions of Restricted Stock Agreements and Option Agreements, and to make
all other determinations in the judgment of the Board necessary or desirable for the administration of the Plan. The Board may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in any Restricted Stock Agreement
or Option Agreement in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the sole and final judge of such expediency. No director or person acting pursuant to authority delegated by the Board shall be
liable for any action or determination under the Plan made in good faith. The Board may, to the full extent permitted by or consistent with applicable laws or regulations, delegate any or all of its powers under the Plan to a committee (the
“Committee”) appointed by the Board, and if the Committee is so appointed all references to the Board in the Plan shall mean and relate to such Committee, other than references to the Board in this sentence and in Section 18 (as to
amendment or termination of the Plan) and Section 21. 

  

	3.	Eligibility. 

 Options may
be granted, and Restricted Stock may be issued, to persons who are, at the time of such grant or issuance, employees, officers or directors of, or consultants or advisors to, the Company; provided, that the class of persons to whom Incentive
Stock Options may be granted shall be limited to employees of the Company. 
  

	 	3.1	 10% Shareholder. If any employee to whom an Incentive Stock Option is to be granted is, at the time of the grant of such Option, the owner of
stock possessing 

  
 A-2

	 	
more than 10% of the total combined voting power of all classes of stock of the Company (after taking into account the attribution of stock ownership rules of Section 424(d) of the Code) (a
“Greater Than 10% Shareholder”), any Incentive Stock Option granted to such individual must: (i) have an exercise price per share of not less than 110% of the fair market value of one share of Common Stock at the time of grant; and
(ii) expire by its terms not more than five years from the date of grant. 

  

	4.	Stock Subject to Plan. 

Subject to adjustment as provided in Section 14.2 below, the maximum number of shares of Common Stock which may be issued under the
Plan is 8,272,373 shares. If an Option shall expire or terminate for any reason without having been exercised in full, the unpurchased shares subject to such Option shall again be available for subsequent Option grants or Restricted Stock Awards
under the Plan. If shares of Restricted Stock shall be forfeited to, or otherwise repurchased by, the Company pursuant to a Restricted Stock Agreement, such repurchased shares shall again be available for subsequent Option grants or Restricted Stock
Awards under the Plan. If shares issued upon exercise of an Option are tendered to the Company in payment of the exercise price of an Option, such tendered shares shall again be available for subsequent Option grants or Restricted Stock Awards under
the Plan. 
  

	5.	Forms of Restricted Stock Agreements and Option Agreements. 

  

	 	5.1	Option Agreement. As a condition to the grant of an Option, each recipient of an Option shall execute an option agreement (“Option Agreement”) in such
form not inconsistent with the Plan as may be approved by the Board of Directors. Such Option Agreements may differ among recipients. 

  

	 	5.2	Restricted Stock Agreement. As a condition to the issuance of Restricted Stock, each recipient thereof shall execute an agreement (“Restricted Stock
Agreement”) in such form not inconsistent with the Plan as may be approved by the Board of Directors. Such Restricted Stock Agreements may differ among recipients. 

 

	 	5.3	“Lock-Up” Agreement. Unless the Board specifies otherwise, each Restricted Stock Agreement and Option Agreement shall provide that upon the request of
the Company or the managing underwriter(s), the holder of any Option or the purchaser of any Restricted Stock shall, in connection with any registration of securities of the Company under the United States Securities Act of 1933, as amended from
time to time (the “Act”), agree in writing that for a period of time (not to exceed 180 days) from the effective date of the registration statement under the Act for such offering, the holder or purchaser will not sell, make any short sale
of, loan, grant any option for the purchase of, or otherwise dispose of any shares of the common stock of the Company owned or controlled by him or her. 

  
 A-3

	6.	Purchase Price. 

  

	 	6.1	General. The purchase price per share of Restricted Stock and per share of stock deliverable upon the exercise of an Option shall be determined by the Board,
provided, however, that in the case of any Option, the exercise price shall not be less than 100% of the fair market value of such stock, as determined by the Board, at the time of grant of such Option, or less than 110% of such fair market value in
the case of any Incentive Stock Option granted to a Greater Than 10% Shareholder. 

  

	 	6.2	Payment of Purchase Price. Option Agreements may provide for the payment of the exercise price by delivery of cash or a check to the order of the Company in an
amount equal to the exercise price of such Options, or, to the extent provided in the applicable Option Agreement, by one of the following methods: 

(i) with the consent of the Board by delivery to the Company of shares of Common Stock; such surrendered shares shall
have a fair market value equal in amount to the exercise price of the Options being exercised, 
 (ii) with the
consent of the Board a personal recourse note issued by the optionee to the Company in a principal amount equal to such aggregate exercise price and with such other terms, including interest rate and maturity, as the Company may determine in its
discretion; provided, however, that the interest rate borne by such note shall not be less than the lowest applicable federal rate, as defined in Section 1274(d) of the Code, 

(iii) with the consent of the Board if the class of Common Stock is registered under the Securities Exchange Act of 1934
at such time, subject to rules as may be established by the Board, by delivery to the Company of a properly executed exercise notice along with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and
acceptable to the Company for the purchase price, 
 (iv) with the consent of the Board by reducing the number
of Option shares otherwise issuable to the optionee upon exercise of the Option by a number of shares of Common Stock having a fair market value equal to such aggregate exercise price; provided, however, that the optionee otherwise holds an equal
number of mature shares, 
 (v) with the consent of the Board by any combination of such methods of payment.

 The fair market value of any shares of the Company’s Common Stock or other non-cash consideration which may be delivered
upon exercise of an Option shall be determined by the Board of Directors. Restricted Stock Agreements may provide for the payment of any purchase price in any manner approved by the Board of Directors at the time of authorizing the issuance thereof.

  
 A-4

	7.	Option Period. 

Notwithstanding any other provision of the Plan or any Option Agreement, each Option and all rights thereunder shall expire on the date
specified in the applicable Option Agreement, provided that such date shall not be later than ten years after the date on which the Option is granted (or five years in the case of an Incentive Stock Option granted to a Greater Than 10% Shareholder),
and in either case, shall be subject to earlier termination as provided in the Plan or Option Agreement. 
  

	8.	Exercise of Options. 

  

	 	8.1	General. Each Option shall be exercisable either in full or in installments at such time or times and during such period as shall be set forth in the agreement
evidencing such Option, subject to the provisions of the Plan. To the extent not exercised, installments shall accumulate and be exercisable, in whole or in part, at any time after becoming exercisable, but not later than the date the Option
expires. 

  

	 	8.2	Notice of Exercise. An Option may be exercised by the optionee by delivering to the Company on any business day a written notice specifying the number of shares
of Common Stock the optionee then desires to purchase and specifying the address to which the certificates for such shares are to be mailed (the “Notice”), accompanied by payment for such shares. In addition, the Company may require any
individual to whom an Option is granted, as a condition of exercising such Option, to give written assurances in a substance and form satisfactory to the Company to the effect that such individual is acquiring the Common Stock subject to the Option
for his or her own account for investment and not with a view to the resale or distribution thereof, and to such other effects as the Company deems necessary or advisable in order to comply with any securities law(s). 

 

	 	8.3	Delivery. As promptly as practicable after receipt of such written notification and payment, the Company shall deliver or cause to be delivered to the optionee
certificates for the number of shares with respect to which such Option has been so exercised, issued in the optionee’s name; provided, however, that such delivery shall be deemed effected for all purposes when the Company or a stock transfer
agent shall have deposited such certificates in the United States mail, addressed to the optionee, at the address specified in the Notice. 

  

	9.	Transferability of Options. 

 No Incentive Stock Option shall be assignable or transferable by the person to whom it is granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and
during the life of an optionee, an Incentive Stock Option shall be exercisable only by the optionee. The Board may, in its discretion, determine the extent to which a non- statutory Option shall be transferable 

  
 A-5

	10.	Termination of Employment; Disability; Death. Except as may be otherwise expressly provided in the terms and conditions of the Option Agreement, Options shall
terminate on the earliest to occur of: 

  

	 	(i)	the date of expiration thereof; 

  

	 	(ii)	90 days after termination of the optionee’s employment with, or provision of services to, the Company by the Company for Cause (as hereinafter defined);

  

	 	(iii)	90 days after the date of voluntary termination of the optionee’s employment with, or provision of services to, the Company by the optionee (other than for death
or permanent disability as defined below); or 

  

	 	(iv)	90 days after the date of termination of the optionee’s employment with, or provision of services to, the Company by the Company without Cause (other than for
death or permanent disability as defined below). 

 Until the date on which the Option so expires, the optionee may exercise that
portion of his or her Option which is exercisable at the time of termination of the employment or service relationship. 
 An
employment or service relationship between the Company and the optionee shall be deemed to exist during any period during which the optionee is employed by or providing services to the Company. Whether an authorized leave of absence or an absence
due to military or government service shall constitute termination of the employment relationship between the Company and the optionee shall be determined by the Board at the time thereof. 

For purposes of this Section 10, the term “Cause” shall mean (a) any material breach by the optionee of any agreement
to which the optionee and the Company are both parties, (b) any act (other than retirement) or omission to act by the optionee which may have a material and adverse effect on the Company’s business or on the optionee’s ability to
perform services for the Company, including, without limitation, the commission of any crime (other than minor traffic violations), or (c) any material misconduct or material neglect of duties by the optionee in connection with the business or
affairs of the Company. 
 In the event of the permanent and total disability or death of an optionee while in an employment or
other relationship with the Company and before the date of expiration of such option, such option shall terminate on the earlier of such date of expiration or one (1) year following the date of such disability or death. After disability or
death, the optionee (or in the case of death, his or her executor, administrator or any person or persons to whom this option may be transferred by will or by laws of descent and distribution) shall have the right, at any time prior to such
termination, to exercise the option to the extent the optionee was entitled to exercise such option as of the date of his or her disability or death. An optionee is permanently and totally disabled if he or she is unable to engage in any substantial
gainful activity by reason of any medically determinable physical or mental impairment which can be expected to last for a continuous period of not less than 12 months; permanent and total disability shall be determined in accordance with
Section 22(e)(3) of the Code and the regulations issued thereunder. 

  
 A-6

	11.	Rights as a Shareholder. The holder of an Option shall have no rights as a shareholder with respect to any shares covered by the Option (including, without
limitation, any rights to receive dividends or non-cash distributions with respect to such shares) until the date of issue of a stock certificate to him or her for such shares. No adjustment shall be made for dividends or other rights for which the
record date is prior to the date such stock certificate is issued. 

  

	12.	Additional Provisions. The Board of Directors may, in its sole discretion, include additional provisions in Restricted Stock Agreements and Option
Agreements, including, without limitation, restrictions on transfer, rights of the Company to repurchase shares of Restricted Stock or shares of Common Stock acquired upon exercise of Options, commitments to pay cash bonuses, to make, arrange for or
guaranty loans or to transfer other property to optionees upon exercise of Options, or such other provisions as shall be determined by the Board of Directors; provided that such additional provisions shall not be inconsistent with any other
term or condition of the Plan and such additional provisions shall not be such as to cause any Incentive Stock Option to fail to qualify as an Incentive Stock Option within the meaning of Section 422 of the Code. 

 

	13.	Acceleration, Extension, Etc. The Board of Directors may, in its sole discretion, (i) accelerate the date or dates on which all or any particular Option or
Options may be exercised or (ii) extend the period or periods of time during which all, or any particular, Option or Options may be exercised. 

  

	14.	Adjustment Upon Changes in Capitalization 

  

	 	14.1	No Effect of Options upon Certain Corporate Transactions. The existence of outstanding Options shall not affect in any way the right or power of the Company to
make or authorize any or all adjustments, recapitalizations, reorganizations or other changes in the Company’s capital structure or its business, or any merger or consolidation, or any issue of Common Stock, or any issue of bonds, debentures,
preferred or prior preference stock ahead of or affecting the Common Stock or the rights thereof, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or
proceeding, whether of a similar character or otherwise. 

  

	 	14.2	 Adjustment Provisions. If, through or as a result of any merger, consolidation, sale of all or substantially all of the assets of the Company,
reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar transaction, (i) the outstanding shares of Common Stock are increased, decreased or exchanged for a different number or kind
of shares or other securities of the Company, or (ii) additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Common Stock or other securities, an
appropriate 

  
 A-7

	 	
and proportionate adjustment shall be made in (x) the maximum number and kind of shares reserved for issuance under the Plan, (y) the number and kind of shares or other securities
subject to any then outstanding Options, and (z) the price for each share or other security subject to any then outstanding Options, so that upon exercise of such Options, in lieu of the shares of Common Stock for which such Options were then
exercisable, the relevant optionee shall be entitled to receive, for the same aggregate consideration, the same total number and kind of shares or other securities, cash or property that the owner of an equal number of outstanding shares of Common
Stock immediately prior to the event requiring adjustment would own as a result of the event. 

  

	 	14.3	No Adjustment in Certain Cases. Except as hereinbefore expressly provided, the issue by the Company of shares of stock of any class, or securities convertible
into shares of stock of any class, for cash or property or for labor or services, either upon direct sale or upon the exercise of rights or warrants to subscribe therefore, or upon conversion of shares or obligations of the Company convertible into
such shares or other securities, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares of Common Stock then subject to outstanding options. 

 

	 	14.4	Board Authority to Make Adjustments. Any adjustments under this Section 14 will be made by the Board of Directors, whose determination as to what
adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued under the Plan on account of any such adjustments. 

 

	15.	Effect of Certain Transactions. 

  

	 	15.1	 General. In the event of a consolidation or merger or sale of all or substantially all of the assets of the Company in which outstanding shares
of Common Stock are exchanged for securities, cash or other property of any other corporation or business entity, or in the event of a liquidation of the Company, the Board, or the board of directors of any corporation assuming the obligations of
the Company, may, in its discretion, take any one or more of the following actions, as to some or all outstanding Options (and need not take the same action as to each such Option): (i) provide that such Options shall be assumed, or equivalent
Options shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), provided that any such Options substituted for Incentive Stock Options shall meet the requirements of Section 424(a) of the Code,
(ii) upon written notice to the optionees, provide that all unexercised Options will terminate immediately prior to the consummation of such transaction unless exercised by the optionee to the extent otherwise then exercisable within a
specified period following the date of such notice, (iii) in the event of a merger under the terms of which holders of the Common Stock of the Company will receive upon consummation thereof a cash payment for each share surrendered in the
merger (the “Merger Price”), make or provide for a cash payment to the optionees equal to the difference between (A) the Merger Price times the number of shares of Common Stock

  
 A-8

	 	
subject to such outstanding Options (to the extent then exercisable at prices not in excess of the Merger Price) and (B) the aggregate exercise price of all such outstanding Options, in
exchange for the termination of such Options, and (iv) provide that all or any outstanding Options shall become exercisable in part or in full immediately prior to such event. 

 

	 	15.2	Substitute Options. The Company may grant Options in substitution for options held by employees of another corporation who become employees of the Company, as
the result of a merger or consolidation of the employing corporation with the Company or as a result of the acquisition by the Company, of property or stock of the employing corporation. The Company may direct that substitute Options be granted on
such terms and conditions as the Board considers appropriate in the circumstances. 

  

	 	15.3	Restricted Stock. In the event of a business combination or other transaction of the type detailed in Section 15.1, any securities, cash or other property
received in exchange for shares of Restricted Stock shall continue to be governed by the provisions of any Restricted Stock Agreement pursuant to which they were issued, including any provision regarding vesting, and such securities, cash, or other
property may be held in escrow on such terms as the Board of Directors may direct, to insure compliance with the terms of any such Restricted Stock Agreement. 

 

	16.	No Special Employment Rights. Nothing contained in the Plan or in any Option or Restricted Stock Agreement shall confer upon any optionee or holder of Restricted
Stock any right with respect to the continuation of his or her employment by the Company or interfere in any way with the right of the Company at any time to terminate such employment or to increase or decrease the compensation of such person.

  

	17.	Other Employee Benefits. The amount of any compensation deemed to be received by an employee as a result of the issuance of shares of Restricted Stock or the
grant or exercise of an Option or the sale of shares received upon such award or exercise will not constitute compensation with respect to which any other employee benefits of such employee are determined, including, without limitation, benefits
under any bonus, pension, profit-sharing, life insurance or salary continuation plan, except as otherwise specifically determined by the Board of Directors. 

 

	18.	Amendment of the Plan. 

  

	 	18.1	The Board may at any time, and from time to time, modify or amend in any respect or terminate the Plan. If shareholder approval is not obtained within twelve months
after any amendment increasing the number of shares authorized under the Plan or changing the class of persons eligible to receive Options under the Plan, no Options granted pursuant to such amendments shall be deemed to be Incentive Stock Options
and no Incentive Stock Options shall be issued pursuant to such amendments thereafter. 

  
 A-9

	 	18.2	The termination or any modification or amendment of the Plan shall not, without the consent of an optionee or the holder of Restricted Stock, adversely affect his or
her rights under an Option or Restricted Stock Award previously granted to him or her. With the consent of the recipient of Restricted Stock or optionee affected, the Board may amend outstanding Restricted Stock Agreements or Option Agreements in a
manner not inconsistent with the Plan. The Board shall have the right to amend or modify the terms and provisions of the Plan and of any outstanding Incentive Stock Options to the extent necessary to qualify any or all such Options for such
favorable federal income tax treatment (including deferral of taxation upon exercise) as may be afforded incentive stock options under Section 422 of the Code. 

 

	19.	Withholding. The Company shall have the right to deduct from payments of any kind otherwise due to the optionee or recipient of Restricted Stock, any federal,
state or local taxes of any kind required by law to be withheld with respect to issuance of any shares of Restricted Stock or shares issued upon exercise of Options. Prior to delivery of any Common Stock pursuant to the terms of this Plan, the Board
has the right to require that the optionee or recipient of Restricted Stock remit to the Company an amount sufficient to satisfy any minimum tax withholding obligation. Subject to the prior approval of the Company, which may be withheld by the
Company in its sole discretion, the obligor may elect to satisfy any minimum withholding obligations, in whole or in part, (i) by causing the Company to withhold shares of Common Stock otherwise issuable, or (ii) by delivering to the
Company a sufficient number of shares of Common Stock. The shares so withheld shall have a fair market value equal to such minimum withholding obligation. The fair market value of the shares used to satisfy such minimum withholding obligation shall
be determined by the Company as of the date that the amount of tax to be withheld is to be determined. A person who has made an election pursuant to this Section 19 may only satisfy his or her withholding obligation with shares of Common Stock
which are not subject to any repurchase, forfeiture, unfulfilled vesting or other similar restrictions. 

  

	20.	Effective Date and Duration of the Plan. 

  

	 	20.1	Effective Date. The Plan shall become effective when adopted by the Board of Directors. If shareholder approval is not obtained within twelve months after the
date of the Board’s adoption of the Plan, no Options previously granted under the Plan shall be deemed to be Incentive Stock Options and no Incentive Stock Options shall be granted thereafter. Amendments to the Plan not requiring shareholder
approval shall become effective when adopted by the Board. Amendments requiring shareholder approval shall become effective when adopted by the Board, but if shareholder approval is not obtained within twelve months of the Board’s adoption of
such amendment, any Incentive Stock Options granted pursuant to such amendment shall be deemed to be non-statutory Options provided that such Options are authorized by the Plan. Subject to this limitation, Options may be granted under the Plan at
any time after the effective date and before the date fixed for termination of the Plan. 

  
 A-10

	 	20.2	Termination. Unless sooner terminated by action of the Board of Directors, the Plan shall terminate upon the close of business on the day next preceding the
tenth anniversary of the date of its adoption by the Board of Directors. 

  

	21.	Requirements of Law. The Company shall not be required to sell or issue any shares under any Option or Restricted Stock Agreement if the issuance of such shares
shall constitute a violation by the optionee, the Restricted Stock Award recipient, or by the Company of any provisions of any law or regulation of any governmental authority. In addition, in connection with the Act, the Company shall not be
required to issue any shares upon exercise of any Option unless the Company has received evidence satisfactory to it to the effect that the holder of such Option will not transfer such shares except pursuant to a registration statement in effect
under the Act or unless an opinion of counsel satisfactory to the Company has been received by the Company to the effect that such registration is not required in connection with any such transfer. Any determination in this connection by the Board
shall be final, binding and conclusive. In the event the shares issuable on exercise of an Option are not registered under the Act or under the securities laws of each relevant state or other jurisdiction, the Company may imprint on the
certificate(s) appropriate legends that counsel for the Company considers necessary or advisable to comply with the Act or any such state or other securities law. The Company may register, but in no event shall be obligated to register, any
securities covered by the Plan pursuant to the Act; and in the event any shares are so registered the Company may remove any legend on certificates representing such shares. The Company shall not be obligated to take any affirmative action in order
to cause the exercise of an Option or the issuance of shares pursuant thereto to comply with any law or regulation of any governmental authority. 

  

	22.	Governing Law. This Plan and each Option or Restricted Stock Agreement shall be governed by the laws of The Commonwealth of Massachusetts, without regard to its
principles of conflicts of law. 

  
 A-11

 NON-STATUTORY STOCK OPTION 

Granted by 

BIND Therapeutics, Inc. (the “Company”) 
 Under the 2006 Stock Incentive Plan 
 This Option is and shall be subject in every
respect to the provisions of the Company’s 2006 Stock Incentive Plan, as amended from time to time, which is incorporated herein by reference and made a part hereof. The holder of this Option (the “Holder”) hereby accepts this Option
subject to all the terms and provisions of the Plan and agrees that (a) in the event of any conflict between the terms hereof and those of the Plan, the latter shall prevail, and (b) all decisions under and interpretations of the Plan by
the Board or the Committee shall be final, binding and conclusive upon the Holder and his or her heirs and legal representatives. 
  

	1.	Name of Holder: 

  

	2.	Date of Grant: 

  

	3.	Maximum number of shares for which this Option is exercisable: 

 

	4.	Exercise (purchase) price per share: 

  

	5.	Payment method:  

 a
personal, certified or bank check or postal money order payable to the order of the Company for an amount equal to the exercise price of the shares being purchased; or 
 with the consent of the Company, any of the other methods set forth in the Plan. 
  

	6.	Expiration Date of this Option:  

  

	7.	Vesting Start Date: 

  

	8.	Vesting Schedule: This Option shall vest and become exercisable for 2 1/12% of the maximum number of shares for which this Option is exercisable on the final day
of the calendar month in which the Vesting Start Date occurs and shall vest and become exercisable for an additional 2 1/12% of such maximum number of shares on the final day of each calendar month thereafter; so that the Option shall become fully
vested and exercisable on                     . All vesting shall cease and any unvested portion of the Option shall be forfeited upon the date of
termination of the Holder’s employment with or provision of services to the Company. 

	9.	Termination of Option. This Option shall terminate on, and may not be exercised by anyone following, the earliest to occur of: 

 

	 	(i)	the Expiration Date of this Option set forth above; 

  

	 	(ii)	90 days after termination of the Holder’s employment with or provision of services to the Company by the Company for Cause (as defined in the Plan);

  

	 	(iii)	90 days after the date of voluntary termination of the Holder’s employment with or provision of services to the Company by the Holder (other than for death or
permanent disability as defined in the Plan); or 

  

	 	(iv)	90 days after the date of termination of the Holder’s employment with or provision of services to the Company by the Company without Cause (other than for death or
permanent disability as defined in the Plan). 

  

	10.	Company’s Right of First Refusal. Prior to the effective date of a registration statement under the Securities Act of 1933, as amended (the “Securities
Act”), covering shares of the Company’s Common Stock, any shares of stock issued pursuant to exercise of this Option shall be subject to the Company’s right of first refusal as set forth at Appendix A. 

 

	11.	Lock-Up Agreement. The Holder agrees for a period of up to 180 days from the effective date of any registration of securities of the Company under the Securities
Act, upon request of the Company or underwriters managing any underwritten offering of the Company’s securities, not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any shares issued pursuant
to the exercise of this Option, without the prior written consent of the Company and such underwriters. 

  

	12.	Tax Withholding. The Company’s obligation to deliver shares shall be subject to the Holder’s satisfaction of any federal, state and local income and
employment tax withholding requirements. 

  

	13.	Notice. Any notice to be given to the Company hereunder shall be deemed sufficient if addressed to the Company and delivered to the office of the Company, BIND
Therapeutics, Inc., 325 Vassar Street, Cambridge, Massachusetts 02139, attention of the president, or such other address as the Company may hereafter designate. Any notice to be given to the Holder hereunder shall be deemed sufficient if addressed
to and delivered in person to the Holder at his or her address furnished to the Company or when deposited in the mail, postage prepaid, addressed to the Holder at such address. 

[signature page follows] 

  
 2 

 IN WITNESS WHEREOF, the parties have executed this Option, or caused this Option to be
executed, as of the Date of Grant. 
  

			
	BIND Therapeutics, Inc.
		
	By:	 	  

		 	Scott Minick

 The undersigned Holder hereby acknowledges receipt of a copy of the Plan and this Option (including Appendix A
hereto), and agrees to the terms of this Option and the Plan. 
  

	
	
	  

	Holder:

 APPENDIX A 
 Right of First Refusal 
 1. General. Prior to the effective
date of a registration statement under the Securities Act of 1933, as amended (the “Securities Act”), covering any shares of the Company’s Common Stock and until such time as the Company shall have effected a public offering of its
Common Stock registered under the Securities Act, in the event that, at any time when the Holder (which term for purposes of this section shall mean the Holder and his or her executors, administrators and any other person to whom this Option may be
transferred by will or the laws of descent and distribution) is permitted to do so, the Holder desires to sell, assign or otherwise transfer any of the shares issued upon the exercise of this Option, the Holder shall first offer such shares to the
Company by giving written notice of the Holder’s desire so to sell, assign or transfer such shares. 
 2. Notice of
Intended Transfer. The notice shall state the number of shares offered, the name of the person or persons to whom it is proposed to sell, assign or transfer such shares and the price at which such shares are intended to be sold, assigned or
transferred. Such notice shall constitute an offer to the Company for the Company to purchase the number of shares set forth in the notice at a price per share equal to the price stated therein. 

3. Company to Accept or Decline Within 30 Days. The Company may accept the offer as to all, but not less than all, such shares by
notifying the Holder in writing within 30 days after receipt of such notice of its acceptance of the offer. If the offer is accepted, the Company shall have 60 days within which to purchase the offered shares at a price per share as aforesaid. If
within the applicable time periods the Holder does not receive notice of the Company’s intention to purchase the offered shares, or if payment in full of the purchase price is not made by the Company, the offer shall be deemed to have been
rejected and the Holder may transfer title to such shares within 90 days from the date of the Holder’s written notice to the Company of the Holder’s intention to sell, but such transfer shall be made only to the proposed transferee and at
the proposed price as stated in such notice and after compliance with any other provisions of this Option applicable to the transfer of such shares. 
 4. Transferred Shares to Remain Subject to Right of First Refusal. Shares that are so transferred to such transferee shall remain subject to the rights of the Company set forth in this Appendix A.
As a condition to such transfer, such transferee shall execute and deliver all such documents as the Company may require to evidence the binding agreement of such transferee so to remain subject to the rights of the Company. 

5. Remedies of Company. No sale, assignment, pledge or transfer of any of the shares covered by this Option shall be effective or
given effect on the books of the Company unless all of the applicable provisions of this Appendix A have been duly complied with, and the Company may inscribe on the face of any certificate representing any of such shares a legend referring to the
provisions of this Appendix A. If any transfer of shares is made or attempted in violation of the foregoing restrictions, or if shares are not offered to the Company as required hereby, the Company shall have the right to purchase such shares from
the owner thereof or his 

 
transferee at any time before or after the transfer, as herein provided. In addition to any other legal or equitable remedies which it may have, the Company may enforce its rights by actions for
specific performance (to the extent permitted by law) and may refuse to recognize any transferee as one of its stockholders for any purpose, including, without limitation, for purposes of dividend and voting rights, until all applicable provisions
hereof have been complied with. 
 6. Shares Subject to Right of First Refusal. For purposes of the Right of First
Refusal pursuant to this Appendix A, the term “shares” shall mean any and all new, substituted or additional securities or other property issued to the Holder, by reason of his or her ownership of Common Stock pursuant to the exercise of
this Option, in connection with any stock dividend, liquidating dividend, stock split or other change in the character or amount of any of the outstanding securities of the Company, or any consolidation, merger or sale of all or substantially all of
the assets of the Company. 
 7. Legends on Stock Certificates. Any certificate representing shares of stock subject to
the provisions of this Appendix A may have endorsed thereon one or more legends, substantially as follows: 
  

	 	(i)	“Any disposition of any interest in the securities represented by this certificate is subject to restrictions, and the securities represented by this certificate
are subject to certain options, contained in a certain agreement between the record holder hereof and the Company, a copy of which will be mailed to any holder of this certificate without charge upon receipt by the Company of a written request
therefor.” 

  

	 	(ii)	“The shares of stock represented by this certificate have not been registered under the Securities Act of 1933 or under the securities laws of any state and may
not be pledged, hypothecated, sold or otherwise transferred except upon such registration or upon receipt by the Company of an opinion of counsel satisfactory to the Company, in form and substance satisfactory to the Company, that such registration
is not required.” 

 8. Right of First Refusal to Lapse Upon Registration. The restrictions imposed by
this Appendix A shall terminate in all respects upon the effective date of a registration statement under the Securities Act covering any of the Company’s Common Stock. 

 INCENTIVE STOCK OPTION 

Granted by 

BIND Therapeutics, Inc. (the “Company”) 
 Under the 2006 Stock Incentive Plan 
 This Option is and shall be subject in every
respect to the provisions of the Company’s 2006 Stock Incentive Plan, as amended from time to time, which is incorporated herein by reference and made a part hereof. The holder of this Option (the “Holder”) hereby accepts this Option
subject to all the terms and provisions of the Plan and agrees that (a) in the event of any conflict between the terms hereof and those of the Plan, the latter shall prevail, and (b) all decisions under and interpretations of the Plan by
the Board or the Committee shall be final, binding and conclusive upon the Holder and his or her heirs and legal representatives. 
  

	1.	Name of Holder: 

  

	2.	Date of Grant: 

  

	3.	Maximum number of shares for which this Option is exercisable: 

  

	4.	Exercise (purchase) price per share:  

  

	5.	Payment method:  

 a
personal, certified or bank check or postal money order payable to the order of the Company for an amount equal to the exercise price of the shares being purchased; or 
 with the consent of the Company, any of the other methods set forth in the Plan. 
  

	6.	Expiration Date of this Option: 

  

	7.	Vesting Start Date: 

  

	8.	Vesting Schedule: This Option shall vest and become exercisable for 25% of the maximum number of shares for which this Option is exercisable on the first
anniversary of the Vesting Start Date and shall vest and become exercisable for an additional 2 1/12% of such maximum number of shares on the final day of each calendar month thereafter; so that the Option shall become fully vested and exercisable
on                     . All vesting shall cease and any unvested portion of the Option shall be forfeited upon the date of termination of the
Holder’s employment with or provision of services to the Company. 

	9.	Termination of Option. This Option shall terminate on, and may not be exercised by anyone following, the earliest to occur of: 

 

	 	(i)	the Expiration Date of this Option set forth above; 

  

	 	(ii)	90 days after termination of the Holder’s employment with or provision of services to the Company by the Company for Cause (as defined in the Plan);

  

	 	(iii)	90 days after the date of voluntary termination of the Holder’s employment with or provision of services to the Company by the Holder (other than for death
or permanent disability as defined in the Plan); or 

  

	 	(iv)	90 days after the date of termination of the Holder’s employment with or provision of services to the Company by the Company without Cause (other than for
death or permanent disability as defined in the Plan). 

  

	10.	Company’s Right of First Refusal. Prior to the effective date of a registration statement under the Securities Act of 1933, as amended (the “Securities
Act”), covering shares of the Company’s Common Stock, any shares of stock issued pursuant to exercise of this Option shall be subject to the Company’s right of first refusal as set forth at Appendix A. 

 

	11.	Lock-Up Agreement. The Holder agrees for a period of up to 180 days from the effective date of any registration of securities of the Company under the Securities
Act, upon request of the Company or underwriters managing any underwritten offering of the Company’s securities, not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any shares issued pursuant
to the exercise of this Option, without the prior written consent of the Company and such underwriters. 

  

	12.	Incentive Stock Option; Disqualifying Disposition. Although this Option is intended to qualify as an incentive stock option under the Internal Revenue Code of
1986, as amended (the “Code”), the Company makes no representation as to the tax treatment upon exercise of this Option or sale or other disposition of the shares covered by this Option, and the Holder is advised to consult a personal tax
advisor. Upon a Disqualifying Disposition of shares received upon exercise of this Option, the Holder will forfeit the favorable income tax treatment otherwise available with respect to the exercise of this Option. A “Disqualifying
Disposition” shall mean a disposition described in Section 421(b) of the Code; as of the date of grant of this Option a Disqualifying Disposition is any disposition (including any sale) of such shares before the later of
(a) the second anniversary of the date of grant of this Option and (b) the first anniversary of the date on which the Holder acquired such shares by exercising this Option, provided that such holding period requirements terminate
upon the death of the Holder. The Holder shall notify the Company in writing immediately upon making a Disqualifying Disposition of any shares of Common Stock received pursuant to the exercise of this Option, and shall provide the Company with any
information that the Company shall request concerning any such Disqualifying Disposition. 

  
 2 

	13.	Notice. Any notice to be given to the Company hereunder shall be deemed sufficient if addressed to the Company and delivered to the office of the Company, BIND
Therapeutics, Inc., 325 Vassar Street, Cambridge, Massachusetts 02139, attention of the president, or such other address as the Company may hereafter designate. Any notice to be given to the Holder hereunder shall be deemed sufficient if addressed
to and delivered in person to the Holder at his or her address furnished to the Company or when deposited in the mail, postage prepaid, addressed to the Holder at such address. 

IN WITNESS WHEREOF, the parties have executed this Option, or caused this Option to be executed, as of the Date of Grant. 

 

			
	BIND Therapeutics, Inc.
		
	By:	 	  

		 	Scott Minick

 The undersigned Holder hereby acknowledges receipt of a copy of the Plan and this Option (including Appendix A
hereto), and agrees to the terms of this Option and the Plan. 
  

	
	
	  
 Holder:

  
 3 

 APPENDIX A 
 Right of First Refusal 
 1. General. Prior to the effective date of
a registration statement under the Securities Act of 1933, as amended (the “Securities Act”), covering any shares of the Company’s Common Stock and until such time as the Company shall have effected a public offering of its Common
Stock registered under the Securities Act, in the event that, at any time when the Holder (which term for purposes of this section shall mean the Holder and his or her executors, administrators and any other person to whom this Option may be
transferred by will or the laws of descent and distribution) is permitted to do so, the Holder desires to sell, assign or otherwise transfer any of the shares issued upon the exercise of this Option, the Holder shall first offer such shares to the
Company by giving written notice of the Holder’s desire so to sell, assign or transfer such shares. 
 2. Notice of
Intended Transfer. The notice shall state the number of shares offered, the name of the person or persons to whom it is proposed to sell, assign or transfer such shares and the price at which such shares are intended to be sold, assigned or
transferred. Such notice shall constitute an offer to the Company for the Company to purchase the number of shares set forth in the notice at a price per share equal to the price stated therein. 

3. Company to Accept or Decline Within 30 Days. The Company may accept the offer as to all, but not less than all, such shares by
notifying the Holder in writing within 30 days after receipt of such notice of its acceptance of the offer. If the offer is accepted, the Company shall have 60 days within which to purchase the offered shares at a price per share as aforesaid. If
within the applicable time periods the Holder does not receive notice of the Company’s intention to purchase the offered shares, or if payment in full of the purchase price is not made by the Company, the offer shall be deemed to have been
rejected and the Holder may transfer title to such shares within 90 days from the date of the Holder’s written notice to the Company of the Holder’s intention to sell, but such transfer shall be made only to the proposed transferee and at
the proposed price as stated in such notice and after compliance with any other provisions of this Option applicable to the transfer of such shares. 
 4. Transferred Shares to Remain Subject to Right of First Refusal. Shares that are so transferred to such transferee shall remain subject to the rights of the Company set forth in this Appendix A.
As a condition to such transfer, such transferee shall execute and deliver all such documents as the Company may require to evidence the binding agreement of such transferee so to remain subject to the rights of the Company. 

5. Remedies of Company. No sale, assignment, pledge or transfer of any of the shares covered by this Option shall be effective or
given effect on the books of the Company unless all of the applicable provisions of this Appendix A have been duly complied with, and the Company may inscribe on the face of any certificate representing any of such shares a legend referring to the
provisions of this Appendix A. If any transfer of shares is made or attempted in 

  
 4 

 
violation of the foregoing restrictions, or if shares are not offered to the Company as required hereby, the Company shall have the right to purchase such shares from the owner thereof or his
transferee at any time before or after the transfer, as herein provided. In addition to any other legal or equitable remedies which it may have, the Company may enforce its rights by actions for specific performance (to the extent permitted by law)
and may refuse to recognize any transferee as one of its stockholders for any purpose, including, without limitation, for purposes of dividend and voting rights, until all applicable provisions hereof have been complied with. 

6. Shares Subject to Right of First Refusal. For purposes of the Right of First Refusal pursuant to this Appendix A, the term
“shares” shall mean any and all new, substituted or additional securities or other property issued to the Holder, by reason of his or her ownership of Common Stock pursuant to the exercise of this Option, in connection with any stock
dividend, liquidating dividend, stock split or other change in the character or amount of any of the outstanding securities of the Company, or any consolidation, merger or sale of all or substantially all of the assets of the Company. 

7. Legends on Stock Certificates. Any certificate representing shares of stock subject to the provisions of this Appendix A may
have endorsed thereon one or more legends, substantially as follows: 
  

	 	(i)	“Any disposition of any interest in the securities represented by this certificate is subject to restrictions, and the securities represented by this certificate
are subject to certain options, contained in a certain agreement between the record holder hereof and the Company, a copy of which will be mailed to any holder of this certificate without charge upon receipt by the Company of a written request
therefor.” 

  

	 	(ii)	“The shares of stock represented by this certificate have not been registered under the Securities Act of 1933 or under the securities laws of any state and may
not be pledged, hypothecated, sold or otherwise transferred except upon such registration or upon receipt by the Company of an opinion of counsel satisfactory to the Company, in form and substance satisfactory to the Company, that such registration
is not required.” 

 8. Right of First Refusal to Lapse Upon Registration. The restrictions imposed by
this Appendix A shall terminate in all respects upon the effective date of a registration statement under the Securities Act covering any of the Company’s Common Stock. 

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]